Cardinal Health Inc. CAH is well-poised for growth, given its long-term supply agreements, diversified product portfolio and ...

congenital adrenal hyperplasia (CAH), a catchall term for genetic mutations that cause abnormal production of hormones by the adrenal glands, including hormones involved in genital development.

“While the data to date are not yet transformational, the study showed for the first time that people living with CAH can indeed make their own cortisol, and that gene therapy can be safely ...

Patients with congenital adrenal hyperplasia (CAH) receiving glucocorticoid therapy showed reduced bone mineral density (BMD), with young adult male patients particularly affected and experiencing ...

With Neurocrine Biosciences having finally shaken up treatment for a rare genetic hormone disease ... for a range of disorders including congenital adrenal hyperplasia (CAH).

HBM Alpha Therapeutics is a company presently developing antibody therapeutics aimed at the rare genetic disease congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).

CAH, with a market capitalization of $30.56 billion ... Early in the year, it introduced Advanced Therapy Connect, a streamlined cell and gene therapy ordering solution. It also became the ...

Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and license agreement with a business partner to advance novel therapies ...